ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

QGEN Qiagen NV

42.11
-0.19 (-0.45%)
Last Updated: 18:31:07
Delayed by 15 minutes
Share Name Share Symbol Market Type
Qiagen NV NYSE:QGEN NYSE Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  -0.19 -0.45% 42.11 42.30 41.49 41.49 1,174,289 18:31:07

QIAGEN N.V. Conference Call on July 13 to Discuss Preliminary Q2 2021 Results

12/07/2021 4:55pm

Business Wire


Qiagen NV (NYSE:QGEN)
Historical Stock Chart


From Apr 2021 to Apr 2024

Click Here for more Qiagen NV Charts.

QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today has released preliminary Q2 2021 results and an updated outlook for full-year 2021.

A conference call is planned for Tuesday, July 13, 2021, at 15:00 CET / 9:00 EDT, hosted by Thierry Bernard, Chief Executive Officer, and Roland Sackers, Chief Financial Officer.

Conference call and webcast details

Interested parties may listen to the call by dialing:

+1 929 477 0402 (U.S.), +44 (0)330 336 9125 (UK), +49 (0) 69 2222 25574 (Germany).

To avoid waiting time, please join the event conference 5-10 minutes prior to the start time. Conference ID: 7999995

The webcast will be accessible at: https://globalmeet.webcasts.com/starthere.jsp?ei=1479747&tp_key=f5369b458c

A conference call replay will be available by using the following link: https://globalmeet.webcasts.com/starthere.jsp?ei=1479747&tp_key=f5369b458c

Contact: IR@qiagen.com

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of March 31, 2021, QIAGEN employed approximately 5,700 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

John Gilardi Vice President Head of Corporate Communications and Investor Relations +49 2103 29 11711 +1 240 686 2222 Email: ir@qiagen.com Phoebe Loh Senior Director Investor Relations +49 2103 29 11457 Email: ir@qiagen.com

1 Year Qiagen NV Chart

1 Year Qiagen NV Chart

1 Month Qiagen NV Chart

1 Month Qiagen NV Chart

Your Recent History

Delayed Upgrade Clock